GCM
MRNS

Graham Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Graham Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-146,215
Closed -$171K – 1402
2024
Q2 		$171K Buy
146,215
+125,651
+611% +$314K ﹤0.01% 884
2024
Q1 		$186K Buy
+20,564
New +$200K ﹤0.01% 913
2023
Q3 		– Sell
-31,162
Closed -$338K – 1350
2023
Q2 		$338K Sell
31,162
-46,901
-60% -$402K 0.01% 647
2023
Q1 		$539K Buy
+78,063
New +$489K 0.02% 732

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Graham Capital Management's MRNS Position: Q3 2024 in Review

Graham Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 146,215 shares — an estimated $171K sold.

Graham Capital Management first reported a position in MRNS in Q1 2023 and held it in 4 quarters. The position peaked at $539K in Q1 2023. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Graham Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 146,215 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $171K.
  • Graham Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2023 and held it in 4 quarters.
  • Graham Capital Management's Marinus Pharmaceuticals, Inc position peaked at $539K in Q1 2023.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.